Publicaciones en colaboración con investigadores/as de Karolinska University Hospital (16)

2022

  1. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505

2021

  1. Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients

    Journal of Clinical Pharmacology, Vol. 61, Núm. 5, pp. 614-627

  2. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

    Haematologica, Vol. 106, Núm. 6, pp. 1725-1732

  3. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

    The Lancet, Vol. 398, Núm. 10301, pp. 665-674

  4. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118

2019

  1. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

    Blood, Vol. 134, Núm. 8, pp. 668-677

2014

  1. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 11, pp. 1195-1206

2011

  1. Multiple myeloma treatment strategies with novel agents in 2011: A European perspective

    Oncologist, Vol. 16, Núm. 4, pp. 388-403

2004

  1. Immunophenotypic approach to the identification and characterization of clonal plasma cells from patients with monoclonal gammopathies

    Journal of Biological Regulators and Homeostatic Agents, Vol. 18, Núm. 3-4, pp. 392-398

2001

  1. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: A retrospective registry study from the European group for blood and marrow transplantation (EBMT)

    Bone Marrow Transplantation, Vol. 27, Núm. 5, pp. 511-515

  2. BIOMED-I concerted action report: Flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings

    Leukemia, Vol. 15, Núm. 8, pp. 1185-1192

2000

  1. BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL)

    Leukemia, Vol. 14, Núm. 5, pp. 816-825

1999

  1. Flow cytometric analysis of normal B cell differentiation: A frame of reference for the detection of minimal residual disease in precursor-B-ALL

    Leukemia, Vol. 13, Núm. 3, pp. 419-427

  2. Immunophenotypical detection of minimal residual disease in acute leukemia

    Critical Reviews in Oncology/Hematology, Vol. 32, Núm. 3, pp. 175-185

  3. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets. Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemia

    Leukemia, Vol. 13, Núm. 1, pp. 110-118

  4. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia

    Leukemia